Products & Pipeline
A pipeline built to prove something: that AI-driven digital medicine can be done rigorously, and at scale.
Three therapeutic areas. Five stages of development. Two certified products already deployed. Every asset built on the same AI platform and to the same regulatory standard, because the standard is the point.
Pipeline
From certified and deployed to early-stage and advancing.
Our pipeline is structured around the pharmaceutical development lifecycle, because that is the model our pharma partners work within, and because it is the most honest way to represent where each asset actually is. All of them are built on the same H.Core AI platform, which means every deployed product generates real-world data that feeds back into improving the clinical models underneath.
| Area / ProgramTherapeutic Area | Indication | Program | Stage |
|---|---|---|---|
| CardiometabolicAmicomed: NWL-001 → | Hypertension | Amicomed: NWL-001 → | In market |
| PainRohkea™: NWL-003 → | Chronic musculoskeletal pain | Rohkea™: NWL-003 → | In market |
| NeurologySoturi: NWL-002 → | Parkinson's levodopa dose management | Soturi: NWL-002 → | Clinical study active |
| NeurologyNWL-004 | Parkinson's companion app | NWL-004 | Clinical study active |
| CardiometabolicNWL-001B | Heart failure | NWL-001B | Proof of concept |
| CardiometabolicNWL-005 | Obesity | NWL-005 | Feasibility |
| CardiometabolicNWL-001C | Pregnancy | NWL-001C | Feasibility |
Pipeline stages: Proof of Concept → Feasibility → Clinical Trial → Certification → In Market
In market today
In market today. Available for partnership.
Our two certified products are available for pharma and health system partners to license, co-brand, and deploy, backed by clinical evidence, regulatory certification, and the post-market infrastructure to keep them compliant over time.
Amicomed
Hypertension Management
CE MDR Class IIaA digital therapeutic for hypertension management, powered by the Pascal algorithm. Validated across 170,000+ measurements and 2,800+ subjects. Demonstrated ~7.9 mmHg mean reduction in systolic BP in uncontrolled hypertensive patients, +50% of patients reaching ideal BP, and −30% reduction in major adverse cardiovascular events.
Learn more →
Rohkea™
Chronic Musculoskeletal Pain
CE MDR Class IIaA VR-based digital therapeutic delivering cognitive behavioral therapy for fear of movement in chronic low back pain patients. Cover study in PAIN Journal. 2–5x higher treatment-responder rate vs. placebo or standard care, with ~70% of patients reporting meaningful perceived improvement.
Learn more →
Soturi
Parkinson's Disease
Clinical study activeA digital ecosystem for personalised Parkinson's care: wearable sensors, digital biomarkers, clinical dashboard, and an AI-driven levodopa dose optimisation decision support system trained on real-world motor fluctuation data. Currently in active clinical study across 3 centres with 60+ patients, backed by $2.5M Phase 1 grant from the Michael J. Fox Foundation.
Learn more →Interested in partnering at any stage of this pipeline?
Whether you want to license a certified product, co-develop an asset in our pipeline, or bring us a new digital therapeutic concept to build and certify, we are open to conversations at any stage.